DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19
30 nov. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
--75% IMPROVEMENT BY DAY 2 ON ARTIVEDA™ AGOURA HILLS, California, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics...
OT-101 PRESENTATION AT PHARMA FORUM 2020
21 sept. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that on...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
23 juin 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
Oncotelic Inc. Announces Appointment of Fatih Uckun MD PhD to Chief Medical Officer
22 janv. 2019 09h15 HE
|
Oncotelic Inc
AGOURA HILLS, Calif, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic), a privately held cancer immunotherapy company dedicated to the discovery and development of in situ cancer...